NCT03317119 - Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2018

Primary Completion Date

July 14, 2023

Study Completion Date

July 14, 2023

Conditions

Metastatic Colon CarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal CarcinomaRAS Family Gene MutationStage III Colon Cancer AJCC v7Stage III Colorectal Cancer AJCC v7Stage III Rectal Cancer AJCC v7Stage IIIA Colon Cancer AJCC v7Stage IIIA Colorectal Cancer AJCC v7Stage IIIA Rectal Cancer AJCC v7Stage IIIB Colon Cancer AJCC v7Stage IIIB Colorectal Cancer AJCC v7Stage IIIB Rectal Cancer AJCC v7Stage IIIC Colon Cancer AJCC v7Stage IIIC Colorectal Cancer AJCC v7Stage IIIC Rectal Cancer AJCC v7Stage IV Colon Cancer AJCC v7Stage IV Colorectal Cancer AJCC v7Stage IV Rectal Cancer AJCC v7Stage IVA Colon Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Stage IVA Rectal Cancer AJCC v7Stage IVB Colon Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7Stage IVB Rectal Cancer AJCC v7

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Trametinib

Given PO

DRUG

Trifluridine and Tipiracil Hydrochloride

Given PO

Trial Locations (8)

91010

City of Hope Medical Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

91345

City of Hope Mission Hills, Mission Hills

91355

City of Hope - Santa Clarita, Santa Clarita

91730

City of Hope Rancho Cucamonga, Rancho Cucamonga

91790

City of Hope West Covina, West Covina

92879

City of Hope Corona, Corona

93534

City of Hope Antelope Valley, Lancaster

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER